Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank75
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Percentile
P75
Within normal range
vs 2Y Ago
-0.2x
Contraction
Streak
1 yr
Consecutive growthContracting
PeriodValueYoY Change
2025-3.66+42.6%
2024-6.38-126.5%
202324.05+246.2%
2022-16.46-20.4%
2021-13.67-